We are fortunate to be backed by institutional investors as well as large medtech players.
In 2019, Sofinnova Partners and MD Start joined forces to launch Sofinnova MD Start III with an initial closing at 48 million euros. Sofinnova MD Start III was
fortunate to receive strong support from returning investors Bpifrance, Medtronic, LivaNova, and
several new investors including the European Investment Fund (EIF) and Baxter Healthcare Corporation. Additionally, it is supported by a number
of world-renowned serial medtech entrepreneurs, all contributing significant
resources and expertise.